Avantor, Inc. (AVTR) Stock: Price, Forecast & Analyst Target
Avantor, Inc. (AVTR) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $14.84 (-1.85%), as of the Nov 20, 2026 trading session; market cap $10.1B. Expected results Feb 10, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 21.75× (cash as of Sep 30, 2026) · expected results Feb 10, 2027
Avantor, Inc. · AVTR · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Avantor supplies laboratories and biopharmaceutical production sites with proprietary and externally sourced materials, consumables, equipment and on-site services; it is more exposed to routine scientific workflows than its instruments-and-supplies classification suggests. The question is whether that recurring demand can restore durable growth and generate enough cash to reduce a debt load that remains far larger than available liquidity.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Avantor (AVTR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- EPS beat 5 of the last 8 reports
- Altman Z 2.15 · Piotroski F 7
- ROE 6.0% · ROA 2.9% · current ratio 1.89 · earnings yield 3.3% · free-cash-flow yield 4.2%
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 63 | Fair | |
| 63 | Fair | |
| 63 | Fair | |
| 71 | Strong | |
| 71 | Strong | |
| 71 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $14.84 | |
| Change on the day | -1.85% | |
| 52-week range | $7.26–$17.45 | |
| Market capitalisation | $10.1B | — |
| Price / earnings (trailing) | 30.29 | |
| Shares traded on the day | 12.25M | |
| Beta (volatility vs the S&P 500) | 0.95 |
Why Avantor scores 71
Share price, last 12 months +36.8%
$11.50 $15.73
What the price assumes
9.8% a year of free-cash-flow growth for ten years is what a $10.66B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $439.20M. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 9 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 11.7% either way.
- +8.6%Feb ’24
- -4.3%Apr ’24
- +15.0%Jul ’24
- -2.7%Oct ’24
- -12.4%Feb ’25
- -19.4%Apr ’25
- -15.9%Aug ’25
- -26.7%Oct ’25
- -18.1%Feb ’26
- +3.1%Apr ’26
- +11.6%Jul ’26
- -2.6%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | -2.6% | -8.6% | |
| Beat | Beat | +11.6% | +7.6% | |
| Beat | Beat | +3.1% | +7.3% | |
| Beat | Beat | -18.1% | -17.5% | |
| Miss | Miss | -26.7% | -23.2% | |
| Miss | Beat | -15.9% | -14.4% | |
| In line | Miss | -19.4% | -17.0% | |
| Beat | Beat | -12.4% | -17.6% | |
| Beat | In line | -2.7% | -4.1% | |
| Beat | In line | +15.0% | +12.2% | |
| Beat | In line | -4.3% | -1.7% | |
| Beat | Beat | +8.6% | +11.1% |
Misses cost real money here: the average first-session move after a miss was -21.3%.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- Getting louder: “ebitda margin” (2 → 6 mentions), “margin expansion” (2 → 4 mentions).
- Gone quiet: “large global”, “vwr com”, “e-commerce platform”, “forward-looking statements” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 53 to 71 while the share price moved +4.1% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Fair → Strong | — | — | — |
The one band change we have recorded has not been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 31% of 26 rate it a buy; the average target sits -2.0% from the price of $14.84.
- Last 90 days: 8 rating actions, every one a reaffirmation.
- Our signals: Strong band; strongest pillar Momentum (95), weakest Financial Safety (32).
Our signals are more constructive than the crowd, led by Momentum.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
As a result, we now expect foreign exchange to contribute approximately 75 basis points to full year reported revenue growth.
Steven W. Eck · Statement from
We anticipate that our adjusted EBITDA margin will expand modestly from Q3 to Q4.
Steven W. Eck · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Avantor (AVTR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Avantor (AVTR), and what does it report?
Short answer · as of
Avantor sells chemicals, reagents, laboratory supplies, process materials, fluid-handling products and specialized services to biopharmaceutical, healthcare, education, government and advanced-technology customers.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Instruments are part of the portfolio, but the business is principally a materials-and-consumables platform serving research, clinical and production workflows.
Reported revenue is divided between Avantor’s proprietary materials and consumables and products sourced from outside manufacturers. Proprietary offerings contribute slightly more revenue, so reported sales combine manufacturing economics with distribution and service activity rather than measuring a pure equipment business.
What do the latest results show for Avantor (AVTR)?
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
The latest reported period brought a sequential revenue rebound and modest growth against the comparable period, while gross profit and operating profit remained below their comparable levels. Net income stayed positive but weakened, leaving the recovery in sales stronger than the recovery in profitability. Revenue and earnings also exceeded consensus in the recent reporting run after a more uneven stretch of surprises.
Management updated its organic revenue outlook, expects currency translation to support reported revenue and retained its free-cash-flow outlook. Those statements describe management’s expectations; the reported record still shows a multi-period annual revenue contraction and an annual loss shaped by a large earlier-period deficit.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.70B Sep 30, 2026
- Latest quarter · SG&A
- $395.30M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $139.50M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $1.70B | Not available | $395.30M | $139.50M |
| Jun 30, 2026 | $1.69B | Not available | $415.20M | $121.80M |
| Mar 31, 2026 | $1.58B | Not available | $0.00 | $115.00M |
| Dec 31, 2025 | $1.66B | Not available | $392.40M | $126.40M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.70B Oct 28, 2026
- Latest report · revenue estimate
- $1.64B Oct 28, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 28, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 28, 2026 | $1.70B | $1.64B | $0.2200 | $0.2090 |
| Jul 29, 2026 | $1.69B | $1.61B | $0.2100 | $0.1915 |
| Apr 29, 2026 | $1.58B | $1.54B | $0.1700 | $0.1570 |
| Feb 11, 2026 | $1.66B | $1.64B | $0.2200 | $0.2100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $1.70B | $203M | $0.30 (diluted) |
| Jun 2026 | $1.69B | $38M | $0.06 (diluted) |
| Mar 2026 | $1.58B | $43M | $0.06 (diluted) |
| Dec 2025 | $1.66B | $52M | $0.08 (diluted) |
What are the financial strengths and risks for Avantor (AVTR)?
Short answer · as of
Cash and short-term investments were $464.30M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $195.10M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Operating cash flow has remained positive throughout the displayed history and strengthened sharply from the preceding period, while capital spending has consumed a comparatively modest share of that inflow. This gives Avantor meaningful cash-generation capacity even though accounting profitability has been disrupted.
Debt towers over cash and short-term investments, leaving the company in a substantial net-debt position. Liquidity ratios indicate coverage of near-term obligations, but the trailing margin set remains negative; weaker demand or another profit shock could therefore slow deleveraging even if operations continue producing cash.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $195.10M Sep 30, 2026
- Previous quarter · operating cash flow
- $178.20M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $195.10M | −$38.90M |
| Jun 30, 2026 | $178.20M | −$37.60M |
| Mar 31, 2026 | $58.70M | −$33.50M |
| Dec 31, 2025 | $152.70M | −$35.50M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Avantor (AVTR)?
Short answer · as of
The next earnings report is expected on Feb 10, 2027. The number it tests is the $0.82 EPS analysts carry for it.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Watch whether proprietary and externally sourced consumables sustain the latest revenue improvement, and whether gross profit and operating profit begin to follow. Another sales beat without comparable profit recovery would point to a weaker earnings mix or cost conversion, although the available figures do not isolate either cause.
Cash conversion is the balance-sheet test: operating cash flow must remain comfortably above capital spending if management’s outlook is to translate into greater debt capacity. Consensus expects the upcoming report to surrender some of the latest revenue level, while the longer forecast path assumes gradual improvement in revenue and earnings.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
In 2026, we now expect an adjusted effective tax rate between 22% and 22.5% and a weighted average diluted share count of 679 million shares.
Steven W. Eck ·
We now expect free cash flow between $520 million and $550 million in 2026, reflecting our year to date financial performance, and the strength and consistency of Avantor's cash generation profile.
Steven W. Eck ·
How does Avantor compare with its peers?
Short answer
Avantor's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Avantor differs from a pure laboratory-instrument manufacturer because much of its revenue comes from materials consumed during research, testing and production rather than from occasional equipment purchases. It also differs from a pure distributor because proprietary chemicals, excipients, silicone materials and bioprocess products contribute slightly more revenue than externally sourced consumables.
That hybrid structure makes customer activity inside laboratories and production facilities more important than equipment replacement alone. Services such as on-site support, sourcing, maintenance and biopharmaceutical scale-up further embed Avantor in customer workflows, but the current financial record shows that this breadth has not prevented revenue contraction.
| Company | Price | Market value | Score |
|---|---|---|---|
| $396.69 Nov 19, 2026 | $27.6B | 92 5-pillar Nov 18, 2026 | |
| $120.16 Nov 20, 2026 | $5.47B | 83 5-pillar Nov 18, 2026 | |
| $84.34 Nov 20, 2026 | $5.05B | 81 5-pillar Nov 18, 2026 | |
| $140.08 Nov 20, 2026 | $8.88B | 77 5-pillar Nov 18, 2026 | |
| $83.52 Nov 20, 2026 | $9.23B | 73 5-pillar Nov 18, 2026 | |
| $172.52 Nov 20, 2026 | $4.31B | 73 5-pillar Nov 18, 2026 | |
| $15.65 Nov 20, 2026 | $4.27B | 73 5-pillar Nov 18, 2026 | |
| Avantor (AVTR) — this page | $14.84 | $10.1B | 71 |
| $163.81 Nov 20, 2026 | $10.5B | 71 5-pillar Nov 18, 2026 | |
| $198.39 Nov 20, 2026 | $10.4B | 68 5-pillar Nov 18, 2026 | |
| $161.58 Nov 20, 2026 | $6.41B | 61 5-pillar Nov 18, 2026 | |
| $25.39 Nov 20, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 | |
| $58.88 Nov 20, 2026 | $11.2B | 40 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $7.00 – $18.00
- Consensus target
- $14.55
- Median target
- $16.00
- Revenue estimate
- $6.67B
- EPS estimate
- $0.82
Consensus record · Captured .
Measured against a quoted price of $14.84 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 10
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 0
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 99.9% Period end Sep 30, 2026
- Reporting holders
- 513 Period end Sep 30, 2026
- Previous quarter · holders
- 471 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Dodge & Cox | 119,275,869 |
| Blackrock, INC. | 70,982,979 |
| Vanguard Portfolio Management LLC | 31,311,591 |
| Vanguard Capital Management LLC | 30,368,763 |
| Dimensional Fund Advisors LP | 24,758,642 |
Tracked investors
Which of the 16 named investors we follow held AVTR in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.09% | $20.87M | Added +360.4% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Avantor (AVTR)?
Avantor Healthcare Stock: Key Questions Answered
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Does Avantor mainly sell laboratory instruments?
Materials, consumables and specialized services form the core of Avantor’s business, while instruments are only part of a broader laboratory and production portfolio. Its segment revenue is entirely classified between proprietary and externally sourced materials and consumables.
What makes Avantor’s proprietary materials important?
Proprietary materials include specialized chemicals, excipients, silicone formulations and bioprocess products used within customer workflows. They contribute slightly more revenue than externally sourced consumables, giving Avantor meaningful product exposure alongside distribution.
Why does biopharmaceutical activity matter to Avantor?
Avantor supplies biopharmaceutical customers with process materials, chromatography products, fluid-handling equipment, clinical kits and development support. Changes in research and production activity can therefore reach product sales and service demand through the same customer workflow.
What would validate Avantor’s updated organic revenue outlook?
Sustained demand across proprietary and externally sourced consumables, accompanied by better gross and operating profit, would make the revenue improvement more convincing. Cash flow remaining well above capital spending would also support management’s retained cash-generation outlook.
What is the AVTR stock price today?
The last price recorded for Avantor, Inc. (AVTR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AVTR price target?
The analyst consensus price target for Avantor, Inc. (AVTR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 77 figures on this page — 2 from SEC filings and earnings calls, 65 from Financial Modeling Prep (FMP), 6 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
